Compare Crispr Therapeutics AG (CRSP) vs ProShares Ultra QQQ ETF (QLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs ProShares Ultra QQQ ETF — how do they compare? Crispr Therapeutics AG trades at $53.51 (market cap $4.88B), while ProShares Ultra QQQ ETF trades at $98.55 (market cap $15.38B). The key difference: ProShares Ultra QQQ ETF is far larger — about 3.2× Crispr Therapeutics AG's market cap, and ProShares Ultra QQQ ETF is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and ProShares Ultra QQQ ETF for 36 Days on average.
| CRSP | QLD | |
|---|---|---|
Market Cap | $4.88B | $15.38B |
Volume | 2,861,747 | 4,844,085 |
Sector | Health | Leveraged / Inverse |
52-Week High | $74.92 | $100.77 |
52-Week Low | $44.34 | $57.16 |
Typical Hold Time | 77 Days | 36 Days |
Enterprise Value | $3.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.41, up 2.02% with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with -$581.60M net income in 2025 and revenue volatility, though analyst consensus remains bullish with a $67.83 price target. Key catalysts include upcoming clinical data presentations for autoimmune disease therapies and CASGEVY commercialization progress.
The stock presents high-risk, high-reward potential with strong Wall Street support (57.9% buy ratings) but faces significant execution risks. Near-term performance hinges on clinical trial outcomes and revenue generation from approved therapies, while persistent cash burn and competitive pressures remain key concerns for investors.
QLD, the ProShares Ultra QQQ ETF, trades at $98.43, down 1.8% on the day, with a bullish technical signal driven by moving averages. The ETF aims to deliver twice the daily return of the Nasdaq-100 Index. Recent news highlights its resilience compared to higher-leverage counterparts during market downturns, with institutional buying noted in Q2 2026.
The outlook hinges on Nasdaq-100 performance and Federal Reserve policy, with support at $96 and resistance at $100. Risks include market volatility and leverage decay. Analyst sentiment is mixed, advising caution until technical confirmation above key moving averages.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →
